Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082847 | 0.95 | OPRM1 (0.46) | OPRM1OPRD1GBA1SIGMAR1HTR2A | |
| SCHEMBL3073767 | 0.93 | GBA1 (0.45) | OPRM1OPRD1GBA1SIGMAR1HTR2A | |
| SCHEMBL3085645 | 0.79 | PDPK1 (0.50) | OPRM1OPRD1GBA1SIGMAR1HTR2A | |
| SCHEMBL3075531 | 0.77 | OPRM1 (0.44) | OPRM1OPRD1GBA1SIGMAR1HTR2A | |
| SCHEMBL7046732 | 0.66 | PDPK1 (0.53) | GBA1SIGMAR1 | |
| SCHEMBL27672080 | 0.66 | S1PR5 (0.71) | OPRM1OPRD1GBA1SIGMAR1HTR2A | |
| SCHEMBL3063424 | 0.64 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL9682520 | 0.64 | GBA1 (0.62) | OPRM1OPRD1GBA1SIGMAR1 | |
| SCHEMBL11227003 | 0.63 | GBA1 (0.61) | OPRM1OPRD1GBA1SIGMAR1 | |
| SCHEMBL7003079 | 0.63 | SLC6A3 (0.61) | GBA1SIGMAR1HTR2AKCNH2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227946-A1 | METHOD OF TREATING INFLAMMATORY, TISSUE REPAIR AND INFECTIOUS CONDITIONS | PERSTORP AB (SE) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227946-A1 | METHOD OF TREATING INFLAMMATORY, TISSUE REPAIR AND INFECTIOUS CONDITIONS | TNF, TLR2, TPMT | OPRM1 1212/4885OPRD1 1743/4885GBA1 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.